FDA Doubts 'Certainty' Of Soy Heart Benefit In First Health Claim Revocation
This article was originally published in The Rose Sheet
Executive Summary
FDA proposed rule would revoke health claims for soy protein and heart disease, the first time the agency has backtracked on an authorized claim. NPA CEO Dan Fabricant says the proposal could sway food and supplement firms to seek qualified health claims rather than invest in research to support authorized health claims.
You may also be interested in...
Avantius Launches Supplement After Study Finds Formulation Slowed Alzheimer’s Progression
Memory Health supplement was developed and is launching in the US after a small European study of Alzheimer’s patients finds improvement in patients taking a carotenoid/omega-3 combination, says marketer Avantius Group. A larger-scale, double blinded clinical study is underway in Europe.
FDA Plans For Soy Health Claims, Pyridoxamine's Use Questioned By CRN, NPA
FDA’s proposed rule to revoke soy protein heart health ignores research supporting the claims and cites evidence that isn't compelling, CRN an NPA say in comments to the agency. CRN also submits comments supporting an ingredient firm's petition asking FDA to remove any uncertainty about the of use of pyridoxamine as a dietary ingredient.
Avon Calling With Espira Supplements: Health And Wellness Industry News
Cosmetics direct sales giant Avon enters the supplement category with Espira; Silk beverages' advertising features swim star Michael Phelps; Nature's Bounty adss Bob Goode as CCO; energy drink Neuenergy promotions link with tennis star Genie Bouchard; and more news in brief.